Drugs / intravenous immunoglobulin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06896253 | Apr 2025 → May 2029 expected | acute myocarditis | Assistance Publique - Hôpitaux de Paris | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | intravenous immunoglobulin | “intravenous immunoglobulin (IVIG) has both antiviral and anti-inflammatory effects on myocarditis.” NCT06896253 ↗ |
| Known as | IVIG | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06896253 ↗ |
| Modality | Protein / enzyme biologic | “intravenous immunoglobulin (IVIG)” NCT06896253 ↗ |
| Route | Intravenous | “0.5g/kg/day IVIG for 4 days.” NCT06896253 ↗ |